APO Research
Talk to an analyst

APO RESEARCH · REPORT

Peramivir

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Peramivir Market Outlook and Growth Opportunities 2026

2 January 2026195 pages

Choose your research edition.

Industry ResearchPeramivir Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Peramivir Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Peramivir Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Peramivir Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Peramivir Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Peramivir market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Peramivir is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Peramivir is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Peramivir is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Peramivir market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Peramivir market include BioCryst Pharmaceuticals, Green Cross Pharma, Hikma Pharmaceuticals, Moksha8 Pharma, NeoPharm, NT Pharma, SCOLR Pharma, Hunan Nucien Pharmaceutical Co., Ltd. and Merck, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Peramivir market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Peramivir and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Peramivir sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Peramivir market size, projected growth trends, production technologies, key applications, and end-use industries.

Peramivir Segment by Company

BioCryst Pharmaceuticals

Green Cross Pharma

Hikma Pharmaceuticals

Moksha8 Pharma

NeoPharm

NT Pharma

SCOLR Pharma

Hunan Nucien Pharmaceutical Co., Ltd.

Merck

Shionogi Co.

Peramivir Segment by Type

Solution

Solid

Peramivir Segment by Application

Influenza A Treatment

Influenza B Treatment

Peramivir Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Peramivir status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Peramivir market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Peramivir significant trends, drivers, influence factors in global and regions.

6. To analyze Peramivir competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peramivir market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Peramivir and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peramivir.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Peramivir market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Peramivir industry.

Chapter 3: Detailed analysis of Peramivir manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Peramivir in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Peramivir in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Peramivir Industry Trends Table 2. Peramivir Industry Drivers Table 3. Peramivir Industry Opportunities and Challenges Table 4. Peramivir Industry Restraints Table 5. Global Peramivir Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Peramivir Revenue Share by Company (2021-2026) Table 7. Global Peramivir Sales Volume by Company (Tons) & (2021-2026) Table 8. Global Peramivir Sales Volume Share by Company (2021-2026) Table 9. Global Peramivir Average Price (US$/Kg) of Company (2021-2026) Table 10. Global Peramivir Company Ranking, (2024-2026) & (USD Million) Table 11. Global Peramivir Key Company Manufacturing Base & Headquarters Table 12. Global Peramivir Company, Product Type & Application Table 13. Global Peramivir Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Peramivir by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Solution Table 18. Significant Companies of Solid Table 19. Global Peramivir Sales Volume by Type 2021 VS 2025 VS 2032 (Tons) Table 20. Global Peramivir Sales Volume by Type (2021-2026) & (Tons) Table 21. Global Peramivir Sales Volume by Type (2027-2032) & (Tons) Table 22. Global Peramivir Sales Volume Share by Type (2021-2026) Table 23. Global Peramivir Sales Volume Share by Type (2027-2032) Table 24. Global Peramivir Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Peramivir Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Peramivir Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Peramivir Sales Value Share by Type (2021-2026) Table 28. Global Peramivir Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Influenza A Treatment Table 30. Significant Companies of Influenza B Treatment Table 31. Global Peramivir Sales Volume by Application 2021 VS 2025 VS 2032 (Tons) Table 32. Global Peramivir Sales Volume by Application (2021-2026) & (Tons) Table 33. Global Peramivir Sales Volume by Application (2027-2032) & (Tons) Table 34. Global Peramivir Sales Volume Share by Application (2021-2026) Table 35. Global Peramivir Sales Volume Share by Application (2027-2032) Table 36. Global Peramivir Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Peramivir Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Peramivir Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Peramivir Sales Value Share by Application (2021-2026) Table 40. Global Peramivir Sales Value Share by Application (2027-2032) Table 41. Global Peramivir Sales by Region: 2021 VS 2025 VS 2032 (Tons) Table 42. Global Peramivir Sales by Region (2021-2026) & (Tons) Table 43. Global Peramivir Sales Market Share by Region (2021-2026) Table 44. Global Peramivir Sales by Region (2027-2032) & (Tons) Table 45. Global Peramivir Sales Market Share by Region (2027-2032) Table 46. Global Peramivir Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Peramivir Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Peramivir Sales Value Share by Region (2021-2026) Table 49. Global Peramivir Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Peramivir Sales Value Share by Region (2027-2032) Table 51. Global Peramivir Market Average Price (US$/Kg) by Region (2021-2026) Table 52. Global Peramivir Market Average Price (US$/Kg) by Region (2027-2032) Table 53. Global Peramivir Sales by Country: 2021 VS 2025 VS 2032 (Tons) Table 54. Global Peramivir Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Peramivir Sales by Country (2021-2026) & (Tons) Table 56. Global Peramivir Sales Market Share by Country (2021-2026) Table 57. Global Peramivir Sales by Country (2027-2032) & (Tons) Table 58. Global Peramivir Sales Market Share by Country (2027-2032) Table 59. Global Peramivir Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Peramivir Sales Value Market Share by Country (2021-2026) Table 61. Global Peramivir Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Peramivir Sales Value Market Share by Country (2027-2032) Table 63. BioCryst Pharmaceuticals Company Information Table 64. BioCryst Pharmaceuticals Business Overview Table 65. BioCryst Pharmaceuticals Peramivir Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 66. BioCryst Pharmaceuticals Peramivir Product Portfolio Table 67. BioCryst Pharmaceuticals Recent Development Table 68. Green Cross Pharma Company Information Table 69. Green Cross Pharma Business Overview Table 70. Green Cross Pharma Peramivir Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 71. Green Cross Pharma Peramivir Product Portfolio Table 72. Green Cross Pharma Recent Development Table 73. Hikma Pharmaceuticals Company Information Table 74. Hikma Pharmaceuticals Business Overview Table 75. Hikma Pharmaceuticals Peramivir Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 76. Hikma Pharmaceuticals Peramivir Product Portfolio Table 77. Hikma Pharmaceuticals Recent Development Table 78. Moksha8 Pharma Company Information Table 79. Moksha8 Pharma Business Overview Table 80. Moksha8 Pharma Peramivir Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 81. Moksha8 Pharma Peramivir Product Portfolio Table 82. Moksha8 Pharma Recent Development Table 83. NeoPharm Company Information Table 84. NeoPharm Business Overview Table 85. NeoPharm Peramivir Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 86. NeoPharm Peramivir Product Portfolio Table 87. NeoPharm Recent Development Table 88. NT Pharma Company Information Table 89. NT Pharma Business Overview Table 90. NT Pharma Peramivir Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 91. NT Pharma Peramivir Product Portfolio Table 92. NT Pharma Recent Development Table 93. SCOLR Pharma Company Information Table 94. SCOLR Pharma Business Overview Table 95. SCOLR Pharma Peramivir Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 96. SCOLR Pharma Peramivir Product Portfolio Table 97. SCOLR Pharma Recent Development Table 98. Hunan Nucien Pharmaceutical Co., Ltd. Company Information Table 99. Hunan Nucien Pharmaceutical Co., Ltd. Business Overview Table 100. Hunan Nucien Pharmaceutical Co., Ltd. Peramivir Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 101. Hunan Nucien Pharmaceutical Co., Ltd. Peramivir Product Portfolio Table 102. Hunan Nucien Pharmaceutical Co., Ltd. Recent Development Table 103. Merck Company Information Table 104. Merck Business Overview Table 105. Merck Peramivir Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 106. Merck Peramivir Product Portfolio Table 107. Merck Recent Development Table 108. Shionogi Co. Company Information Table 109. Shionogi Co. Business Overview Table 110. Shionogi Co. Peramivir Sales (Tons), Value (US$ Million), Price (US$/Kg) and Gross Margin (2021-2026) Table 111. Shionogi Co. Peramivir Product Portfolio Table 112. Shionogi Co. Recent Development Table 113. Key Raw Materials Table 114. Raw Materials Key Suppliers Table 115. Peramivir Distributors List Table 116. Peramivir Customers List Table 117. Research Programs/Design for This Report Table 118. Authors List of This Report Table 119. Secondary Sources Table 120. Primary Sources List of Figures Figure 1. Peramivir Product Image Figure 2. Global Peramivir Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Peramivir Sales Value (2021-2032) & (US$ Million) Figure 4. Global Peramivir Sales (2021-2032) & (Tons) Figure 5. Global Peramivir Sales Average Price (US$/Kg) & (2021-2032) Figure 6. Global Peramivir Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Solution Image Figure 10. Solid Image Figure 11. Global Peramivir Sales Volume by Type (2021 VS 2025 VS 2032) & (Tons) Figure 12. Global Peramivir Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Peramivir Sales Volume Share by Type (2021-2032) Figure 14. Global Peramivir Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Peramivir Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Peramivir Sales Value Share by Type (2021-2032) Figure 17. Influenza A Treatment Image Figure 18. Influenza B Treatment Image Figure 19. Global Peramivir Sales Volume by Application (2021 VS 2025 VS 2032) & (Tons) Figure 20. Global Peramivir Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Peramivir Sales Volume Share by Application (2021-2032) Figure 22. Global Peramivir Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Peramivir Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Peramivir Sales Value Share by Application (2021-2032) Figure 25. Global Peramivir Sales by Region: 2021 VS 2025 VS 2032 (Tons) Figure 26. Global Peramivir Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Peramivir Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Peramivir Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Peramivir Sales Value (2021-2032) & (US$ Million) Figure 30. North America Peramivir Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Peramivir Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Peramivir Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Peramivir Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Peramivir Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Peramivir Sales Value (2021-2032) & (US$ Million) Figure 36. South America Peramivir Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Peramivir Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Peramivir Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Peramivir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Peramivir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Peramivir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Peramivir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Peramivir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Peramivir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Peramivir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Peramivir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Peramivir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Peramivir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Peramivir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Peramivir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Peramivir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Peramivir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Peramivir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Peramivir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Peramivir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Peramivir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Peramivir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Peramivir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Peramivir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Peramivir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Peramivir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Peramivir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Peramivir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Peramivir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Peramivir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Peramivir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Peramivir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Peramivir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Peramivir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Peramivir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Peramivir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Peramivir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Peramivir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Peramivir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Peramivir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Peramivir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Peramivir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Peramivir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Peramivir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Peramivir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Peramivir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Peramivir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Peramivir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Peramivir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Peramivir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Peramivir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Peramivir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Peramivir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Peramivir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Peramivir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Peramivir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Peramivir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Peramivir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Peramivir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Peramivir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Peramivir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Peramivir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Peramivir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Peramivir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Peramivir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Peramivir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Peramivir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Peramivir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Peramivir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Peramivir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Peramivir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Peramivir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Peramivir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Peramivir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Peramivir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Peramivir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Peramivir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Peramivir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Peramivir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Peramivir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Peramivir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Peramivir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Peramivir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Peramivir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Peramivir Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Peramivir Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Peramivir Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Peramivir Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Peramivir Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Solution
  • Solid
Applications
  • Influenza A Treatment
  • Influenza B Treatment
Companies covered
  • BioCryst Pharmaceuticals
  • Green Cross Pharma
  • Hikma Pharmaceuticals
  • Moksha8 Pharma
  • NeoPharm
  • NT Pharma
  • SCOLR Pharma
  • Hunan Nucien Pharmaceutical Co., Ltd.
  • Merck
  • Shionogi Co.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Peramivir Sales Value (2021-2032)
  4. 1.2.2 Global Peramivir Sales Volume (2021-2032)
  5. 1.2.3 Global Peramivir Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Peramivir Market Dynamics
  1. 2.1 Peramivir Industry Trends
  2. 2.2 Peramivir Industry Drivers
  3. 2.3 Peramivir Industry Opportunities and Challenges
  4. 2.4 Peramivir Industry Restraints
3 Peramivir Market by Company
  1. 3.1 Global Peramivir Company Revenue Ranking in 2025
  2. 3.2 Global Peramivir Revenue by Company (2021-2026)
  3. 3.3 Global Peramivir Sales Volume by Company (2021-2026)
  4. 3.4 Global Peramivir Average Price by Company (2021-2026)
  5. 3.5 Global Peramivir Company Ranking (2024-2026)
  6. 3.6 Global Peramivir Company Manufacturing Base and Headquarters
  7. 3.7 Global Peramivir Company Product Type and Application
  8. 3.8 Global Peramivir Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Peramivir Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Peramivir Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Peramivir Market by Type
  1. 4.1 Peramivir Type Introduction
  2. 4.1.1 Solution
  3. 4.1.2 Solid
  4. 4.2 Global Peramivir Sales Volume by Type
  5. 4.2.1 Global Peramivir Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Peramivir Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Peramivir Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Peramivir Sales Value by Type
  9. 4.3.1 Global Peramivir Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Peramivir Sales Value by Type (2021-2032)
  11. 4.3.3 Global Peramivir Sales Value Share by Type (2021-2032)
5 Peramivir Market by Application
  1. 5.1 Peramivir Application Introduction
  2. 5.1.1 Influenza A Treatment
  3. 5.1.2 Influenza B Treatment
  4. 5.2 Global Peramivir Sales Volume by Application
  5. 5.2.1 Global Peramivir Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Peramivir Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Peramivir Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Peramivir Sales Value by Application
  9. 5.3.1 Global Peramivir Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Peramivir Sales Value by Application (2021-2032)
  11. 5.3.3 Global Peramivir Sales Value Share by Application (2021-2032)
6 Peramivir Regional Sales and Value Analysis
  1. 6.1 Global Peramivir Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Peramivir Sales by Region (2021-2032)
  3. 6.2.1 Global Peramivir Sales by Region: 2021-2026
  4. 6.2.2 Global Peramivir Sales by Region (2027-2032)
  5. 6.3 Global Peramivir Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Peramivir Sales Value by Region (2021-2032)
  7. 6.4.1 Global Peramivir Sales Value by Region: 2021-2026
  8. 6.4.2 Global Peramivir Sales Value by Region (2027-2032)
  9. 6.5 Global Peramivir Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Peramivir Sales Value (2021-2032)
  12. 6.6.2 North America Peramivir Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Peramivir Sales Value (2021-2032)
  15. 6.7.2 Europe Peramivir Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Peramivir Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Peramivir Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Peramivir Sales Value (2021-2032)
  21. 6.9.2 South America Peramivir Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Peramivir Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Peramivir Sales Value Share by Country, 2025 VS 2032
7 Peramivir Country-level Sales and Value Analysis
  1. 7.1 Global Peramivir Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Peramivir Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Peramivir Sales by Country (2021-2032)
  4. 7.3.1 Global Peramivir Sales by Country (2021-2026)
  5. 7.3.2 Global Peramivir Sales by Country (2027-2032)
  6. 7.4 Global Peramivir Sales Value by Country (2021-2032)
  7. 7.4.1 Global Peramivir Sales Value by Country (2021-2026)
  8. 7.4.2 Global Peramivir Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Peramivir Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Peramivir Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Peramivir Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Peramivir Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Peramivir Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Peramivir Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Peramivir Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Peramivir Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Peramivir Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Peramivir Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Peramivir Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Peramivir Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Peramivir Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Peramivir Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Peramivir Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Peramivir Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Peramivir Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Peramivir Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Peramivir Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Peramivir Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Peramivir Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Peramivir Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Peramivir Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Peramivir Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Peramivir Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Peramivir Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Peramivir Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Peramivir Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Peramivir Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Peramivir Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Peramivir Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Peramivir Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Peramivir Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Peramivir Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Peramivir Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Peramivir Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Peramivir Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Peramivir Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Peramivir Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Peramivir Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Peramivir Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Peramivir Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Peramivir Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Peramivir Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Peramivir Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Peramivir Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Peramivir Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Peramivir Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Peramivir Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Peramivir Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Peramivir Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Peramivir Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Peramivir Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Peramivir Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Peramivir Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Peramivir Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Peramivir Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Peramivir Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Peramivir Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Peramivir Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Peramivir Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Peramivir Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Peramivir Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Peramivir Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Peramivir Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Peramivir Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Peramivir Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Peramivir Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Peramivir Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Peramivir Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Peramivir Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Peramivir Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Peramivir Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Peramivir Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Peramivir Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Peramivir Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Peramivir Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Peramivir Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Peramivir Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Peramivir Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Peramivir Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Peramivir Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Peramivir Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Peramivir Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 BioCryst Pharmaceuticals
  2. 8.1.1 BioCryst Pharmaceuticals Company Information
  3. 8.1.2 BioCryst Pharmaceuticals Business Overview
  4. 8.1.3 BioCryst Pharmaceuticals Peramivir Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 BioCryst Pharmaceuticals Peramivir Product Portfolio
  6. 8.1.5 BioCryst Pharmaceuticals Recent Developments
  7. 8.2 Green Cross Pharma
  8. 8.2.1 Green Cross Pharma Company Information
  9. 8.2.2 Green Cross Pharma Business Overview
  10. 8.2.3 Green Cross Pharma Peramivir Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Green Cross Pharma Peramivir Product Portfolio
  12. 8.2.5 Green Cross Pharma Recent Developments
  13. 8.3 Hikma Pharmaceuticals
  14. 8.3.1 Hikma Pharmaceuticals Company Information
  15. 8.3.2 Hikma Pharmaceuticals Business Overview
  16. 8.3.3 Hikma Pharmaceuticals Peramivir Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Hikma Pharmaceuticals Peramivir Product Portfolio
  18. 8.3.5 Hikma Pharmaceuticals Recent Developments
  19. 8.4 Moksha8 Pharma
  20. 8.4.1 Moksha8 Pharma Company Information
  21. 8.4.2 Moksha8 Pharma Business Overview
  22. 8.4.3 Moksha8 Pharma Peramivir Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Moksha8 Pharma Peramivir Product Portfolio
  24. 8.4.5 Moksha8 Pharma Recent Developments
  25. 8.5 NeoPharm
  26. 8.5.1 NeoPharm Company Information
  27. 8.5.2 NeoPharm Business Overview
  28. 8.5.3 NeoPharm Peramivir Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 NeoPharm Peramivir Product Portfolio
  30. 8.5.5 NeoPharm Recent Developments
  31. 8.6 NT Pharma
  32. 8.6.1 NT Pharma Company Information
  33. 8.6.2 NT Pharma Business Overview
  34. 8.6.3 NT Pharma Peramivir Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 NT Pharma Peramivir Product Portfolio
  36. 8.6.5 NT Pharma Recent Developments
  37. 8.7 SCOLR Pharma
  38. 8.7.1 SCOLR Pharma Company Information
  39. 8.7.2 SCOLR Pharma Business Overview
  40. 8.7.3 SCOLR Pharma Peramivir Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 SCOLR Pharma Peramivir Product Portfolio
  42. 8.7.5 SCOLR Pharma Recent Developments
  43. 8.8 Hunan Nucien Pharmaceutical Co., Ltd.
  44. 8.8.1 Hunan Nucien Pharmaceutical Co., Ltd. Company Information
  45. 8.8.2 Hunan Nucien Pharmaceutical Co., Ltd. Business Overview
  46. 8.8.3 Hunan Nucien Pharmaceutical Co., Ltd. Peramivir Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Hunan Nucien Pharmaceutical Co., Ltd. Peramivir Product Portfolio
  48. 8.8.5 Hunan Nucien Pharmaceutical Co., Ltd. Recent Developments
  49. 8.9 Merck
  50. 8.9.1 Merck Company Information
  51. 8.9.2 Merck Business Overview
  52. 8.9.3 Merck Peramivir Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Merck Peramivir Product Portfolio
  54. 8.9.5 Merck Recent Developments
  55. 8.10 Shionogi Co.
  56. 8.10.1 Shionogi Co. Company Information
  57. 8.10.2 Shionogi Co. Business Overview
  58. 8.10.3 Shionogi Co. Peramivir Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Shionogi Co. Peramivir Product Portfolio
  60. 8.10.5 Shionogi Co. Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Peramivir Value Chain Analysis
  2. 9.1.1 Peramivir Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Peramivir Sales Mode & Process
  6. 9.2 Peramivir Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Peramivir Distributors
  9. 9.2.3 Peramivir Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst